MedDataX Logo

Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers

NCT ID: NCT03504475

Last Updated: 2018-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

53 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-29

Study Completion Date

2018-06-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to compare the rate and extent of absorption of paroxetine hydrochloride 20 mg tablets (test) and Paxil® (reference) administered as 20 mg tablet under fed conditions.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design is an Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study with a washout period of 14 days. During each session, the subjects will be administered a single dose of 20 mg Paroxetine (one Paroxetine Hydrochloride Tablet 20mg or one Paxil® Tablet 20 mg) under Fasting and Fed conditions. Venous blood samples will be collected at pre-dose (0 h), and up to 96 h post dose.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depressive Disorder Obsessive-Compulsive Disorder Panic Disorder Social Anxiety Disorder Generalized Anxiety Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Paroxetine Hydrochloride Tablet

During the study session, healthy subjects will be administered a single dose of Paroxetine Hydrochloride Tablet 20mg under Fasting and Fed conditions.

Group Type EXPERIMENTAL

Paroxetine Hydrochloride Tablet 20 mg

Intervention Type DRUG

A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.

Paxil®

During the study session, healthy subjects will be administered a single dose of Paxil® 20mg under Fasting and Fed conditions.

Group Type ACTIVE_COMPARATOR

Paxil® 20 mg

Intervention Type DRUG

Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Paroxetine Hydrochloride Tablet 20 mg

A generic product manufactured by Beijing Winsunny Pharmaceutical Co., Ltd.

Intervention Type DRUG

Paxil® 20 mg

Paxil® Tablet 20 mg will be used as a comparator drug for the bioequivalence study, manufactured by GlaxoSmithKline（Distributed by: Apotex Corp.）.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Paroxetine Hydrochloride Tablet 20 mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects are fully informed and voluntarily consent to participate in this study.
2. Healthy adult volunteers of ≥18 years old and ≤ 65 years old, male or female.
3. Body weight ≥ 50.0 kg for male and 45.0 kg for female , and body mass index (BMI) ranges from 19.0 to 28.0 kg/m2(including).
4. The results of physical examination, vital signs examination, clinical laboratory examination (blood routine, urine routine, blood biochemistry), 12-lead electrocardiogram (ECG), chest radiograph were normal or no clinical significant.

Exclusion Criteria

1. Allergy or hypersensitivity to paroxetine or components in the formulation, or have clear history of drug allergies, or have been diagnosed with allergic constitution.
2. History of any diseases which could interfere with the clinical safety or the process in vivo of the drug, such as liver, kidney, cardiovascular, tuberculosis, epilepsy, asthma, diabetes or glaucoma disease, especially the endocrine disease, gastrointestinal disease, gastrointestinal surgery, or unresolved gastrointestinal symptoms (such as diarrhea, vomiting).
3. Present of any unstable or recurrent diseases , or diseases that interfere with the process in vivo of the drug.
4. History of drug abuse/dependence, drug-taking, or positive urine drug screen at screening.
5. Significant alcohol abuse within 2 years ( more than two units of alcohol per day, drink at least 14 units of alcohol per week: 1 unit = 285 mL of beer or 120 mL of white spirit or 25 mL of spirit or 100 mL of wine) ,or positive alcohol exhalation test at screening.
6. Smoking within 1 year (more than 5 cigarettes per day), or could not avoid smoking during the study period started from signing the informed consent forms.
7. Use of any medication changed the liver enzyme activity within the 28 days prior to the study.
8. Use of any medication within 14 days prior to the study.
9. With special diet (including grapefruit and/or xanthine, etc.) or vigorous exercise, or other factors that affected the drug absorption/distribution/metabolism/excretion within 14 days prior to the study.
10. Volunteer in any other clinical drug study within 90 days prior to the study.
11. Blood donation or lost more than 200 mL of blood within 90 days prior to the study.
12. History of needlesickness or hematophobia, or cannot tolerate venipuncture.
13. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test.
14. Have the family fertility plan, unwilling or unable to take effective contraceptive methods to prevent pregnancy from 30 days before the study until 6 months after the end of study.
15. Positive Human chorionic gonadotropin (HCG) results for female, or lactating women.
16. Have special diet, cannot control diet and exercise as requested.
17. Other situations that the researchers considered unsuitable to enroll the subject.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Beijing Winsunny Pharmceutical Co.,Ltd.

UNKNOWN

Sponsor Role collaborator

Beijing Tongren Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Xiuli Zhao, PhD

Role: PRINCIPAL_INVESTIGATOR

Beijing Tongren Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing TongRen Hospital

Beijing, Beijing Municipality, China

Site Status

Beijing TongRen Hospital

Beijing, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WS-CP-06-201709-01

Identifier Type: -

Identifier Source: org_study_id